INTRODUCTION: Cryptogenic strokes, the majority of which are brought on by an embolic mechanism, are a subset of ischemic stroke that affects around 25% of all patients. In people with a history of cryptogenic or left atrial cardiomyopathy and unknown stroke who are on anticoagulant therapy, rivaroxaban may reduce the chance of having another stroke compared to aspirin. METHODS: The effectiveness and tolerability of rivaroxaban and aspirin in preventing recurrent stroke in individuals with a history of left atrial cardiomyopathy and cryptogenic stroke were compared in this cross-sectional investigation. RESULTS: The odds ratio for stroke recurrence with aspirin treatment was 11 times higher than with rivaroxaban therapy, even after controlling for other factors such as age, gender, hypertension, and diabetes with the p-value of 0.038 and 95% confidence interval range of 1.39 to 113.08 and OR value of 11.35CONCLUSIONS: In individuals with a history of unknown etiology stroke and left atrial cardiomyopathy, rivaroxaban was more effective than aspirin at preventing recurrent stroke.
Keywords: atrial cardiomyopathy, aspirin, stroke.